2025 China Cancer Vaccine Market Revenue Opportunities Report
Description
The 2025 China Cancer Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer vaccine market in China include Shanghai Zerun Biotechnology, Xiamen Innovax Biotechnology, Cure & Sure Biotech, and several multinational pharmaceutical companies such as Merck & Co. These companies lead the development and commercialization of cancer vaccines targeting different cancer types and HPV serotypes. Shanghai Zerun developed Wozehui and Xiamen Innovax developed Cecolin, both HPV vaccines. Cure & Sure Biotech’s Rebys is an autologous therapeutic vaccine targeting multiple cancers including esophageal, stomach, pancreatic, and liver cancers. Multinational companies contribute four approved vaccines, evidencing significant foreign presence alongside local players.
China’s cancer vaccine market is rapidly growing, valued at USD 560.7 million in 2023 and projected to reach over USD 1.3 billion by 2030 with a CAGR of 12.9%. Local firms are advancing therapeutic cancer vaccines, comprising over 60% of candidates in clinical trials, reflecting a robust pipeline. The market includes personalized neoantigen vaccines and mRNA platforms driven by innovation from both Chinese and multinational companies. China is the fastest-growing regional market in Asia Pacific and expected to lead the regional and global oncology influence as these vaccines commercialize.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer vaccine market in China include Shanghai Zerun Biotechnology, Xiamen Innovax Biotechnology, Cure & Sure Biotech, and several multinational pharmaceutical companies such as Merck & Co. These companies lead the development and commercialization of cancer vaccines targeting different cancer types and HPV serotypes. Shanghai Zerun developed Wozehui and Xiamen Innovax developed Cecolin, both HPV vaccines. Cure & Sure Biotech’s Rebys is an autologous therapeutic vaccine targeting multiple cancers including esophageal, stomach, pancreatic, and liver cancers. Multinational companies contribute four approved vaccines, evidencing significant foreign presence alongside local players.
China’s cancer vaccine market is rapidly growing, valued at USD 560.7 million in 2023 and projected to reach over USD 1.3 billion by 2030 with a CAGR of 12.9%. Local firms are advancing therapeutic cancer vaccines, comprising over 60% of candidates in clinical trials, reflecting a robust pipeline. The market includes personalized neoantigen vaccines and mRNA platforms driven by innovation from both Chinese and multinational companies. China is the fastest-growing regional market in Asia Pacific and expected to lead the regional and global oncology influence as these vaccines commercialize.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
